USCOM LIMITED — Annual Report 2016

Aug 28, 2016

==> picture [88 x 98] intentionally omitted <==

Uscom (UCM) – Global Medical Devices

Annual Results FY 2016

Rob Phillips

PhD(med), MPhil(med), FASE, DMU(cardiol) Associate Professor, Critical Care Research Group, School of Medicine, The University of Queensland Uscom Executive Chairman/CEO

The Measure of Life

Disclaimer

This presentation is intended to provide a general outline only and is not intended to be a definitive statement on the subject matter. The information in this presentation, whether written or verbal, has been prepared without taking into account the commercial, financial or other needs of any individual or organisation.

While Uscom (the "Company”) has taken due care in compiling the information, neither the Company nor its officers or advisors or any other person warrants the accuracy, reliability, completeness or timeliness of the information or guarantees the commercial or investment performance of the Company. Certain information may relate to protected intellectual property rights owned by Uscom. By viewing this presentation the viewer accepts the terms of the Company NDA. The information does not constitute advice of any kind and should not be relied on as such. Investors must make their own independent assessment of the Company and undertake such additional enquiries as they deem necessary or appropriate for their own investment purposes. Any and all use of the information is at your own risk.

==> picture [37 x 44] intentionally omitted <==

2

Uscom

“Improving physician effectiveness and patient outcomes with practice changing noninvasive medical devices.”

==> picture [192 x 198] intentionally omitted <==

==> picture [173 x 135] intentionally omitted <==

==> picture [232 x 159] intentionally omitted <==

New generation digital cardiovascular and pulmonary devices.

==> picture [37 x 44] intentionally omitted <==

Uscom – Medical devices the experts use

3

Uscom – 2016

Not only growth: Record revenue, sales, cash, share price, cap value (+44 to114%) But investment in the future: Transformational $65m 5yr agreement Acquired Thor laboratories and consolidated into Uscom Non recurring investment in:

acquisition and integration (≈$1m) two new product lines for sale in 2017 (≈$0.5m) global corporate model Approaching profitability

==> picture [37 x 44] intentionally omitted <==

4

Uscom – Medical devices the experts use

UCM – 2016 Results

Total Revenue

==> picture [380 x 276] intentionally omitted <==

----- Start of picture text -----

$3,500,000
$2,936,504
$3,000,000
$2,500,000
$2,039,426
$2,000,000
$1,500,000 $1,377,716
$1,010,942
$1,000,000 $864,099
$500,000
$0
2012 2013 2014 2015 2016
----- End of picture text -----

2016 – Total revenue up 44% to $2.94m (43% CAGR for 3 years)

==> picture [37 x 44] intentionally omitted <==

9

Right company, right time…..

• Estimate

UCM – 2016 Results

Receipts from Customers

==> picture [375 x 284] intentionally omitted <==

----- Start of picture text -----

2,563,145
2,500,000
2,000,000
1,500,000
1,321,080
$
1,000,000
829,424
621,253
500,000
-
2013 2014 2015 2016
----- End of picture text -----

2016 – Receipts from Customers up 94% to $2.56m (60% CAGR for 3 years)

==> picture [37 x 44] intentionally omitted <==

9

Right company, right time…..

• Estimate

UCM – 2016 Results

==> picture [475 x 319] intentionally omitted <==

----- Start of picture text -----

Cash, Equity and Assets
6,000,000
5,711,746
4,937,991
5,000,000
4,000,000
2,936,355
$ 3,000,000 2,839,773 2015
2016
2,288,661
2,000,000
1,290,796
992,796
1,000,000
526,317
0
Cash Cash Spend Equity Assets
----- End of picture text -----

2016 – A year of investment

Right company, right time…..

==> picture [37 x 44] intentionally omitted <==

9

• Estimate

UCM – 2016 Results

Quarterly Total Revenue

==> picture [333 x 258] intentionally omitted <==

----- Start of picture text -----

900000
800000
700000
600000
500000
$
400000
300000
200000
100000
0
Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4
13 13 14 14 14 14 15 15 15 15 16 16 16 16
----- End of picture text -----

Quarterly Cash Receipts

==> picture [333 x 257] intentionally omitted <==

----- Start of picture text -----

700,000
600,000
500,000
400,000
$
300,000
200,000
100,000
0
Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4
13 13 14 14 14 14 15 15 15 15 16 16 16 16
----- End of picture text -----

2016 – Total Revenue and Cash Receipts CAGR 44% and 94% CAGR 3 years

==> picture [37 x 44] intentionally omitted <==

9

Right company, right time…..

• Estimate

UCM – 2016 Results

UCM Growth FY 2016

UCM YTD 2016

==> picture [692 x 303] intentionally omitted <==

----- Start of picture text -----

120 114
100
80
61
% 60 81 67
% %
40
20
0
Share Price Cap value
UCM share price +61% (15.5-25c)
Cap value +114% ($12.2m-$27.1m)
----- End of picture text -----

==> picture [66 x 79] intentionally omitted <==

UCM continues to outperform the ASX and Health Sector

9

BellDirect 24[th] August 2016

UCM – 2016 Results

2016 – Share Price 15.5 to 25 (+61%) To date – 15.5 to 32.5 (+110%)

UCM FPO 2016

Record 2016 with two new product lines and CIIC agreement to impact in 2017

==> picture [66 x 79] intentionally omitted <==

==> picture [192 x 46] intentionally omitted <==

9

BellPotter 24[th] August 2016 July 2015 to June 2016

UCM – 2016 Results

Perfomance FY2016 Indices, Top 10 Superannuation funds and UCM

==> picture [710 x 335] intentionally omitted <==

----- Start of picture text -----

70
61
60
50
Indices Top 10 Super Funds
40
30
20 16.3
10.6
10 7.6 7 5.9 5.7 5.5 5.5 5.4 5.1 5 4.5
0
-2.3
-10 -5.2
-7.5
-10.1
-20
-30 -25.8
-40
The Top 10 Australian Superannuation Funds,
"Australian”, Financial Services, p22, 20th July 2016
% Growth
----- End of picture text -----

==> picture [37 x 39] intentionally omitted <==

26

A simple comparison…..

BellPotter 24[th] August 2016

Uscom

“Time and again we find similar traits among long-term winners:

1. Led by founders with their fortunes and legacies on the line 2. Debt free and scalable operations 3. Willing to disrupt themselves 4. Have zealous, loyal customers.”

Joe Magyer Australian Financial Review 22 June 2016

==> picture [37 x 44] intentionally omitted <==

12

Uscom – Medical devices the experts use

Uscom – 2016

What we did: A year of record growth (40-90%) $65m 5yr deal signed for 2017 (2016 rev $3m) Acquired and paid for Thor Laboratories Consolidated Thor and established global reporting Established a global corporate model Non recurring spend on acquisition and integration Increased cash on hand Developed two new product lines for sale in 2017 Approaching profitability

==> picture [37 x 44] intentionally omitted <==

13

Uscom – Medical devices the experts use

Products USCOM 1A

Heart failure, hypertension, sepsis, fluid Non invasive, accurate, compact, platform technology

Accurate cardiac output Cardiac stroke volume Systemic vascular resistance Left + right heart measurement

==> picture [285 x 232] intentionally omitted <==

Works with all other hospital equipment Intuitive touch screen Real time data

Platform technology with multiple uses

Non invasive, real time, beat-to-beat haemodynamics

Uscom – Devices the experts use

==> picture [37 x 44] intentionally omitted <==

14

New Products

==> picture [120 x 70] intentionally omitted <==

Hypertension, heart failure and vascular disease Central Blood Pressure and Pulse Wave Analysis The new standard for hypertension

• FDA, CE Mark, TGA approvals

• Supra-systolic Oscollometry

• Reliable and

• • accurate

• • Central and

• • Brachial BP

• • Replaces sub-systolic methods (cuff)

==> picture [261 x 165] intentionally omitted <==

----- Start of picture text -----

•
•
•
•
•
----- End of picture text -----

• Home or clinic

• PPW Analysis

• Results in

• 30 seconds

• No training required • Platform technology with multiple uses

Stand alone, non invasive, accurate, compact system with BP+Reporter

Uscom – Devices the experts use

==> picture [37 x 44] intentionally omitted <==

15

New Products

Series Digital Ultrasonic Spirometry New Standards of Pulmonary Testing

Devices Applications Software

==> picture [111 x 99] intentionally omitted <==

==> picture [104 x 111] intentionally omitted <==

==> picture [153 x 109] intentionally omitted <==

==> picture [163 x 109] intentionally omitted <==

==> picture [41 x 48] intentionally omitted <==

==> picture [41 x 47] intentionally omitted <==

==> picture [55 x 111] intentionally omitted <==

For launch FY 2017

Uscom – Devices the experts use

==> picture [245 x 185] intentionally omitted <==

==> picture [37 x 44] intentionally omitted <==

16

New Products tSpiro

Uscom sells technologies others are only researching High fidelity digital ultrasonic spirometers The future for asthma, COPD, occuational lung disease and eHealth,

==> picture [55 x 111] intentionally omitted <==

• CE, FDA and TGA. CFDA (in submission)

• US revenue (more than 400 sold)

• Software analytics

• Telemetric signals to cloud via iphone

• Cloud based processing/diagnosis

==> picture [40 x 34] intentionally omitted <==

• Connecting patients to clinicians

==> picture [245 x 184] intentionally omitted <==

• Personalised clinical advice - medication and dosage

• Serial monitoring

• Multiple measure trending

• Home care market

• Capital and subscription revenue

• Global partners – China, US, Euro

• Multiple software providers – few hardware providers

Aus - Resapp (RAP) – Cap $240m, Adherium (ADR) – Cap $77m, Uscom (UCM) – Cap $35m US - Cohero, Gecko, Asthma Sense, Propeller Health

==> picture [37 x 44] intentionally omitted <==

17

1. Uscom Sydney

2. Uscom London

Uscom Global

1. Uscom Budapest

2. Uscom LA

Delivering multiple products into multiple jurisdictions

1. Uscom Shanghai

2 •[•] • •[•][ •] • •• 3

[•] • • • • •[•] •

[•] • •

[•] • 4 • • •

• • • 5 • • •

•

•

Key Markets Asia

Europe Nth America

•

• • •[•]

Focus FY 2017

==> picture [11 x 14] intentionally omitted <==

----- Start of picture text -----

1
----- End of picture text -----

Asia – Establish CIIC US – BP+ and SpiroSonic release Global tSpiro partnerships

==> picture [37 x 44] intentionally omitted <==

18

China is Important

CIIC to distribute $65m of Uscom devices and support regulatory over 5 yrs

==> picture [101 x 147] intentionally omitted <==

State funded growth

China Health Spend (USD) GDP=12,000,000,000,000 Health=5.4%=648,000,000,000 Objective=12%=1,400,000,000,000 Growth(+6.6%)=$792,000,000,000

China Health Expenditure as % of GDP 7.9 6.5 5.1 5.0 5.1[5.4] 4.6[4.84.8][ 4.7 4.7] 4.6 4.4[4.6]

Uscom China Targets (USD) Population = 1.35b 3 provinces < 10% pop = $10m 31 Provinces = 100% 10 x current UCM revenue = $10m 2 new products = $20m Total revenue China = $30m USD

==> picture [48 x 84] intentionally omitted <==

Uscom positioning to grow with China - $30m pa revenue target

==> picture [37 x 44] intentionally omitted <==

19

CIIC China

==> picture [54 x 65] intentionally omitted <==

==> picture [97 x 59] intentionally omitted <==

“We plan to make Uscom one of the leading medical device brands in China over the next five years.”

Daniel Sun, Head of BD and Marketing, Shanghai CIIC Science and Technology, Medical Device division

==> picture [37 x 44] intentionally omitted <==

20

Uscom – Medical devices the experts use

CIIC China

==> picture [98 x 60] intentionally omitted <==

==> picture [549 x 366] intentionally omitted <==

http://www.bloomberg.com/news/articles/2016-07-05/china-inc-goes-on-a-buying-spree-for-global-health-care-assets

==> picture [37 x 44] intentionally omitted <==

21

Uscom – Medical devices the experts use

Uscom CIIC China Agreement

==> picture [54 x 65] intentionally omitted <==

==> picture [443 x 211] intentionally omitted <==

==> picture [97 x 60] intentionally omitted <==

• 5 year importation and wholesale agreement with Shanghai CIIC Science and Technology Development Corp targeted to generate A$65m sales.

==> picture [166 x 39] intentionally omitted <==

==> picture [132 x 26] intentionally omitted <==

==> picture [85 x 42] intentionally omitted <==

==> picture [83 x 26] intentionally omitted <==

==> picture [127 x 37] intentionally omitted <==

CIIC S&T – State owned company CIIC revenue – $10b USD, Med Device Division $250m USD

==> picture [37 x 44] intentionally omitted <==

22

Uscom – Medical devices the experts use

Recent Media

==> picture [310 x 174] intentionally omitted <==

Alan Kohler

Peter Switzer Fox TV

==> picture [321 x 176] intentionally omitted <==

==> picture [141 x 107] intentionally omitted <==

CNBC Asia Tom Piotrowski Uscom – Medical devices the experts use

==> picture [37 x 44] intentionally omitted <==

23

Recent Media

==> picture [392 x 399] intentionally omitted <==

==> picture [315 x 44] intentionally omitted <==

With improved operational performance has come increased media and international investor interest

The Australian, 5-3-16 Sarah-Jane Tasker

==> picture [37 x 44] intentionally omitted <==

24

Uscom – 2016

Not only growth: Record revenue, sales, cash, share price, cap value (+44 to114%) But investment in the future: Transformational $65m 5yr agreement Acquired Thor laboratories and consolidated into Uscom Non recurring investment in:

acquisition and integration (≈$1m) two new product lines for sale in 2017 (≈$0.5m) global corporate model Approaching profitability

==> picture [37 x 44] intentionally omitted <==

25

Uscom – Medical devices the experts use

UCM – 2016 Results

" Investors can review Uscom’s progress in 2016 with satisfaction and look forward to the rewards of 2017 and beyond. Uscom has invested in the future, and an investment in Uscom is an investment in the future.”

==> picture [37 x 44] intentionally omitted <==

26

Uscom – Medical devices the experts use

Uscom – 2017

What we are going to do: Deliver two new revenue streams – BP+, SpiroSonic Increase sales to China through CIIC ($65m - 5 yrs) Early US and Euro BP+ and SpiroSonic sales Continue growing USCOM 1A sales Grow our distribution and marketing network

==> picture [37 x 44] intentionally omitted <==

27

Uscom – Medical devices the experts use

Uscom – 2017

Three world leading product ranges entering profit phase

	Concept	Product	Pilot	Validation	Regulatory	Revenue	Global Distribution		Profit FY17
USCOM 1A	✓	✓	✓	✓	✓	✓	✓		±✓
Uscom BP+	✓	✓	✓	✓	✓	✓	✓		±✓
SpiroSonic	✓	✓	✓	✓	✓	✓	✓		✓

Investment to Profit

IP transformed into profit

==> picture [37 x 44] intentionally omitted <==

26

Uscom – 2017

Regulatory - Uscom has prepared a new generation of products for approval and sale across multiple jurisdictions in 2017

==> picture [675 x 349] intentionally omitted <==

----- Start of picture text -----

New revenue 2017
USCOM 1A Uscom BP+ SpiroSonic
CE (Europe) 2017 2017
✓
FDA (USA) 2017 2017
✓
CFDA (China) 2017 2017
✓
TGA (Aus) 2017 2017
✓
----- End of picture text -----*

• Subject to regulatory approval

Uscom – Devices the experts use

29

Revenue Targets

==> picture [626 x 388] intentionally omitted <==

----- Start of picture text -----

SpiroSonic – FY 2017
Total Revenue
20,000,000
18,000,000
16,000,000 BP+ - FY 2017
14,000,000
12,000,000
SpiroSonic
$ 10,000,000
BP+
USCOM
8,000,000 USCOM
6,000,000
4,000,000
2,000,000
0
2015 2016 2017 2018 2019 2020
----- End of picture text -----*

$20m revenue by 2020 = 5 year CAGR of 58%

==> picture [37 x 44] intentionally omitted <==

30

Uscom - 2017

"Uscom has acquired global assets to ensure reliable revenue growth for investors for the coming decade.

For 2017 our strategy is to deliver the devices we have acquired into global markets. We are confident that this will drive our revenue growth and underwrite long term profitability.”

==> picture [37 x 44] intentionally omitted <==

31

Uscom – Medical devices the experts use

Annual Results – 2016

”Record growth for 2016, with two new revenue streams and CIIC distribution in 2017.”

==> picture [37 x 44] intentionally omitted <==

32

Uscom – Medical devices the experts use

==> picture [88 x 98] intentionally omitted <==

Uscom (UCM) – Global Medical Devices

Annual Results FY 2016

Thank You

Rob Phillips

PhD(med), MPhil(med), FASE, DMU(cardiol) Associate Professor, Critical Care Research Group, School of Medicine, The University of Queensland Executive Chairman/CEO

Uscom – Medical devices the experts use

Business Background

• Premium noninvasive cardiovascular and pulmonary monitoring devices

• Addressing the growing threat of superbugs, heart failure, hypertension and asthma

• Validated, clinically accepted, cost and life saving devices with critical applications

• Aggressive global growth strategy – acquisition and partnerships

• IP protected and FDA, CE and CFDA regulatory approvals

• Uscom BP+ and SpiroSonic for market FY 2017

• $3m revenue 2016, $65m 5year deal starts 2017

Corporate  ASX listed (UCM)  Headquartered in Sydney  Market cap of $35m  108m shares on issue  Rob Phillips, Founder and CEO, holds 18% of company		Board & Management  Rob Phillips, Chairman & CEO  Sheena Jack, Director (HCF, Moneytime Health)  Christian Bernecker, Director (Stream)  David He, Director (J&J, McKinseys)  Nick Schicht, General Manager		Financials  Sales +94% 2016  Revenue +44% 2016 ($3m)  Cash consumption - $1.2m  Gross Margins ~ 75%  Cash ~ $2.8m

==> picture [37 x 44] intentionally omitted <==

34

• Uscom Annual report

Products

Multiple high fidelity noninvasive digital medical devices

Fluid, Sepsis

& Heart Failure

• US $1.3bn market[*]

• CAGR of 7.6%[*]

• CE, FDA, TGA, CFDA

Hypertension & COPD Vascular Health

& Asthma

• US $1.7bn market[*]

• US $400m market[*]

• CAGR of 11.5%[*]

• CAGR of 6.5%[*]

• CE, FDA, TGA

• CE, TGA, FDA

USCOM 1A

BP+

Cardiac Output Monitoring Blood Pressure Monitoring

SpiroSonic Pulmonary Monitoring

==> picture [136 x 106] intentionally omitted <==

==> picture [116 x 118] intentionally omitted <==

==> picture [214 x 147] intentionally omitted <==

Uscom – Devices the experts use

35

• Source: MedTech Insight; Transparency Market Research

USCOM 1A Competitive Advantage

Method	Manufacturer	Technology	Rel+Rep	Non- invasive	Simple	Cost	Portable	SV beat to beat
USCOM 1A	Uscom	Doppler	✓	✓	✓	✓	✓	✓
BioZ	Samsung	BioImpedance	✗	✓	✓	✗	✓	✗
NiCOM	Cheetah	BioReactance	✗	✓	✓	✗	✓	✗
Nexfin	Bmeye	APP	✗	✓	✓	✓	✓	✗
CardioQ	Deltex	Doppler	✓	✗	✓	✗	✓	✗
LiDCO	LiDCO	LiCl dilutio +APP	✓	✗	✗	✗	✗	✗
LiDCOrapid	LiDCO	APP	✗	✗	✓	✗	✗	✗
PiCCO (mod Tx + PP)	Pulsion	APP	✓	✗	✗	✗	✗	✗
FloTrac	Edwards	APP	✗	✗	✗	✗	✗	✗
PAC (Tx)	Many	Thermodilution	✗	✗	✗	✗	✗	✗

==> picture [37 x 44] intentionally omitted <==

36

Testimonials

“This machine is saving lives, there are no two ways about it.”

Professor Brendan Smith, Anesthetist, Intensivist and Emergency Physician, N.S.W. Dept of Health, Australia

“USCOM has changed the way I look at the cardiovascular status of my patients.

It’s part of the initial shock evaluation and monitored regularly thereafter…. USCOM has now been established as the standard of care.”

Dr Akash Deep, Director of Paediatric ICU, King's College Hospital, London

“The USCOM device is a simple method of accurately and noninvasively measuring central circulation, a goal of cardiology for many years. The device has the potential to change the way we approach management of sepsis, heart failure and hypertension.”

Professor Malcolm West, Cardiologist, Mayne Professor of Medicine at The University of Queensland School of Medicine, Brisbane, Australia and Uscom Medical Advisory Board Member.

“I have used USCOM for over 5 years now on our very sick children, and use it to guide management. We are now beginning multi-centre, global research which will define the way USCOM is used in Paediatric Departments across the world.”

Dr Joe Brierley, Consultant Intensivist, Great Ormond Street Hospital for Sick Children, London, UK.

“The USCOM device is really good; I use it in all my aneasthetics. I think there should be one on every ICU bed and on every anaesthetic patient.”

Dr Steve Woodford, Consultant Anaesthetist, circulatory researcher at Australian School of Advanced Medicine, and Uscom Investor,

“To parents and doctors this machine, USCOM, is priceless. This machine is thought to have saved baby Abbie’s life.

BBC Documentary “New machine helps save babies life”, 2010, Nottingham Children’s Hospital

==> picture [37 x 44] intentionally omitted <==

37

Uscom – Medical devices the experts use

==> picture [163 x 195] intentionally omitted <==

BP+ Competitive Advantage

==> picture [87 x 88] intentionally omitted <==

==> picture [121 x 83] intentionally omitted <==

==> picture [125 x 81] intentionally omitted <==

==> picture [97 x 69] intentionally omitted <==

Uscom BP+	TensioMed	BPLab	IEM	Centron	AtCor
Australia	Hungary	Russia	Germany	UK	Australia
USD 3,500	USD 6,000	USD 7,000	USD 7,000	USD 6,300	USD 20,000
1 min	2 min	2 min	2 min	1 min	1 min
Stand-alone	ABP, needs computer	ABP, needs computer	ABP, needs computer	Stand-alone	Needs computer
CE, FDA, TGA	CE	CE	CE, FDA	CE	CE, FDA
Aortic + brachial waveform	Central systolic BP	Rough waveform	Rough waveform	Rough waveform	Rough waveform
Physical model	Statistical regression	Transfer function	Transfer function	Transfer function	Transfer function

Uscom – Medical devices the experts use

38

Why ?

Independent research from Cambridge University, Weill Cornell, University of California, Wales Heart Institute – BP+ = Four stars

==> picture [604 x 274] intentionally omitted <==

BP+ is on the international space station

==> picture [37 x 44] intentionally omitted <==

36

McEniery CM, Cockcroft JR, Roman MJ, Franklin SS, Wilkinson AB. Central blood pressure: current evidence and clinical importance. Euro Heart J 2014;doi10.1093/ eurojeartj/eht565

SpiroSonic Competitive Advantage

==> picture [139 x 43] intentionally omitted <==

==> picture [112 x 77] intentionally omitted <==

==> picture [88 x 72] intentionally omitted <==

==> picture [90 x 67] intentionally omitted <==

==> picture [74 x 80] intentionally omitted <==

==> picture [70 x 70] intentionally omitted <==

==> picture [82 x 81] intentionally omitted <==

==> picture [69 x 72] intentionally omitted <==

==> picture [92 x 70] intentionally omitted <==

Uscom SpiroSonic	Welch Allyn	Schiller	Sibelmed	Vitalograph	MIR	Carefusion	NDD
Australia	USA	Switzerland	Spain	USA	Italy	USA	Switzerland
SpiroSonic	SpiroPerfect	Spirovit SP-1	Dataspir Touch	Pneumotrac	Spirodoc	Microloop	EasyOne PLus
USD 1,890	USD 2,100	USD 1,850	USD 2,300	USD 2,030	USD 1,580	USD 2,180	USD 1,990
Dual Path Ultrasound	Diff Pressure	Diff Pressure	Turbine	Diff Pressure	Turbine	Turbine	Single Path Ultrasound
Accurate Auto calibration SpiroReporter Fully digital FreeFlo sensor Hygeinic SpO2 Bluetooth Rechargeable	Multiple iterations	Multiple iterations	Multiple iterations	Multiple iterations	Multiple iterations Conssumable turbines	Multiple iterations	Accurate Consumable tube

40

Uscom – Medical devices the experts use

CPT Codes and Re-Imbursement

Product	Measure	Region	Code	Price(AUD)	Status
Uscom BP+	Central BP	USA	93050	$25.60	S*
USCOM 1A	Cardiac Output	USA	76999	$107.00	S**
	Cardiac Output	China	310701023	$44.00	✓
	Cardiac Output	China	220600010	$13.50 + $2.50 measure	✓
	Cardiac Output	Australia	TBD	TBD	S**
Uscom Thor	Spirometry	USA	94010	$51.43	✓
	Spirometry	USA	94060	$87.14	✓
	Spirometry	USA	94070	$87.00	✓
	Spirometry	USA	94375	$57.14	✓
	Spirometry	Australia	11506	$20.55	✓
	Spirometry	Australia	11509	$35.65	✓
	Spirometry	Australia	11512	$61.75	✓

S[] Subject to Software modification and FDA notification S[*] Under submission TBD –To be determined

Big Data

Big data needs high quality sensors Uscom specialises in high quality non-invasive sensors

==> picture [83 x 87] intentionally omitted <==

• Software analytics

==> picture [58 x 61] intentionally omitted <==

• Telemetric signals

• Cloud based processing/diagnosis

• Personalised clinical advice

==> picture [82 x 82] intentionally omitted <==

• Medication and dosage

==> picture [41 x 48] intentionally omitted <==

• Serial monitoring

• Multiple measures

• Home care market

==> picture [58 x 60] intentionally omitted <==

• Subscription service model

==> picture [132 x 126] intentionally omitted <==

• Global partner opportunities – China, US, Euro

• Multiple software providers – few hardware providers

Stand alone, wireless, accurate, compact, digital devices

==> picture [37 x 44] intentionally omitted <==

Uscom – Devices the experts use

42